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Summary: Homovanillic acid is extracted from 0.5 ml serum with ethyl acetate at acidic pH, and its pentafluoro-
propionic anhydride and hexafluoroisopropanol derivative injected into a 3% SE-30 column at 140 °C, fitted with
an electron capture detector. In a group of normal volunteers (n = 42) a mean value of 62 ± 45 jug/1 was found. The
distribution of the serum concentrations was found to be bimodal. Using the same procedure for the homovanillic
acid estimation in cerebrospinal fluid (CSF), mean values of 73.0 ± 41 ßg/i serum and 68 ± 36 %/\ CSF were found
for a group of 22 untreated patients with paranoid-hallucinatory syndrome. After treatment with neuroleptics, for 1
week to 1 month, the homovanillic acid concentration increased significantly only in the CSF. By the procedure
described, other acidic metabolites of biogenic amines are extracted together with homovanillic acid and can also be
estimated in the same sample.
Gaschromatographische Bestimmung von Homovanillinsäure im Serum Gesunder und psychotischer Patienten
Zusammenfassung: Homovanülinsäure wird aus 0.5 ml Serum mit Ethylacetat bei saurem pH extrahiert und nach
Derivatisierung mit Pentafluorpropionsäureanhydrid und Hexafluorisopropanol auf einer 3% SE-30 Säule gaschroma-
tographisch getrennt und mit Elektroneneinfangdetektor bestimmt. Für eine Gruppe von Normalpersonen (n = 42)
wurde ein Mittelwert von 62 ± 45 #g/l Serum ermittelt, und die Verteilung der Konzentrationen war bimodal. Die
gleiche Methode kann für die Homo vanillinsäure Bestimmung im Liquor cerebrospinalis angewandt werden. In einer
Gruppe psychotischer Patienten mit paranoid-halluzinatorischem Syndrom (n = 22), unbehandelt, wurden Mittel-
werte von 73 ± 41 /zg/1 Serum und 68 ± 36 g/l Liquor gefunden. Nach Behandlung mit Neuroleptika kam es zu einer




acid) is considered to be the main metabolite of dopa-
mine in the brain. It has been detected in brain tissue and
cerebrospinal fluid (CSF) ( —3) and its concentration in
CSF may reflect the central dopamine turnover (for
review see I.e. (4)).
Dopamine is metabolized by the alternative action of
monoamine pxidase and catechol-Q-methyltransferase;
the 0-methylated and oxidatively deaminated product,
an aldehyde, is further oxidized to the acid by aldehyde
dehydrogenase. The O-methylation can take place at the
4-QH group of dopamine, whereby isö-hömovanillic acid
is produced. It has been detected in small amounts in
CSF (5, 6).
An active transport system, sensitive to probenecid,
removes homovanillic acid from the brain to CSF and
from CSF to the blood (7). It is localized in the region of
the fourth ventricle (8). In CSF, there is a gradient in the
homovanillic acid concentration: in man, the concentra-
tion falls from 466 £/1 in the ventricular CSF to 185 in
the cisternal and to 53 /ig/1 in the lumbar CSF (9). In
lumbar CSF, the concentration of homovanillic acid
depends greatly on the conditions under which the
puncture was performed (position of the patient,
restriction of movement for several hours before punc-
ture, amount of fluid taken).
Urinary concentrations of homovanillic acid do not
correlate with CSF concentrations (10) and it is still
unknown which part of urinary homovanillic acid
originates from central dopamine turnover. Its estimation
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in the intermediate fluid, blood, could give further
information on dopamine metabolism, especially on
changes during pharmacological studies.
Methods of homovanillic acid estimation used until now
were based on the fluorimetric determination of homo-
vanillic acid isolated by column chromatography. They
were used for the estimation in CSF, brain tissue and
urine (1, 7, 11, 12, 13). A gas Chromatographie method
for the estimation of homovanillic acid in CSF has been
described (14), using an electron capture detector,
following derivatization with pentafluoropropionic an-
hydride and hexafluoroisopropanol.
We developed a simple and efficient method for the
estimation of homovanillic acid in serum, using an
appropiate column for its separation from the other
serum constituents, which was sensitive enough to allow
the estimation in 0.5 ml serum.
We estimated homovanillic acid in the serum of normals,
and in the serum and CSF of psychotic patients, before
and after treatment with neuroleptics, in order to see
how far serum homovanillic acid concentrations
reflect eventual changes in dopamine turnover.
Method
E x t r a c t i o n a n d d e r i v a t i z a t i o n
0.5 ml serum is diluted with 1 ml water and 0.1 ml 1 mol/1 HC1
is added to bring the pH to between 1.5 and 2.0. 3 ml ethyl
acetate are added; the mixture is shaken for 5 minutes, ihen
centrifuged to separate the phases. The ethyl acetate phase is
removed with a pasteur pipette and the procedure is repeated
two more times. The combined extracts are evaporated to
dry ness in an evapo-mix (Buchler Instr., Fort Lee, U.S.A.).
0.1 ml pentafluoroproponic anhydride and 0.1 ml hexafluoroiso-
propanol (both from Pierce Chemicals, U*S.A.) are added and
incubated for 10 minutes at 60 °C. The excess reagent is
evaporated with a gentle nitrogen flow (smell test) and the prod-
uct dissolved in 1 ml dry ethyl acetate.
G a s c h r o m a t o g r a p h y
2 μΐ are injected into a gas Chromatographie system (Hewlett-
Packard 7602A, with automatic injection system and integrator)
with an electron capture detector (nickel) and a coiled glass
column 6 feet X 4 mm, packed with chromosorb WAW DMCS
80-100 mesh, coated with 3% SE-30. The column temperature
is set at 140 °C, detector and injection port at 180 °C Carrier
gas flow rate 40 ml/h (helium), argon-methane (10%) flow rate
40 ml/h. Under these conditions the retention time for homo-
vanillic acid is 6 minutes.
We use the same procedure for the homovanillic acid estimation
in CSF, with the only difference that in this case 0.04 ml HC1
are added to bring the pH to less than 2.0.
For the calculation of the homovanillic acid concentrations, we
use the difference in response (peak height) when authentic
homovanillic acid is added in the sample at the beginning of the
procedure.
Figure 1 shows a chromatogram of a serum extract with and
without internal standard.
Results
The reproducibility of the method was found to be very
good: In a 5 fold estimation we found, using the
integrator counts to express the response, a mean value
for the homovanillic acid peak of 50,494 ± 5,366 counts,
with a range 43,010 to 57,610 counts, and a variation
coefficient of 10.6%. The variation in the response of
homovanillic acid added as internal standard was found
to be of the same order.
After incubation with glusulase to hydrolyze any sulfate
or glucuronate conjugates of homovanillic acid that may
be present, we found no increase in the amount of
homovanillic acid. This indicates that at least 90% of
the serum homovanillic acid is present in the free form.
The recovery of added homovanillic acid was calculated
by comparing the response obtained from a certain
amount of internal standard with the response of the
0.5 ml eerum
+ 100 ng HVA
Fig. 1. Gas chromatograms of serum extracts without (a) and with (b) internal standard (0.5 ml serum + 100 ng homovanillic acid).
Retention time of homovanillic acid (HVA) = 6 min.
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same amount of homovanillic acid incubated as dry
substance and was found to be 70—75 per cent.
Variation of the serum volume from 0.25 ml to 1.0 ml
gave a linear correlation to the homovanillic acid response
(r = 0.9559), and variation of the amount of internal
standard from 50 to 200 μ§/1 gave a linear correlation
with r = 0.9790.
The other acidic metabolites of biogenic amines are
extracted and derivatized together with homovanillic
acid and must appear in the chromatogram. We found
that 3-methoxy-4-hydroxymandelic acid runs in the
chromatogram close to and before homovanillic acid.
Its response was five times lower than that of homo-
vanillic acid. We found the 3-methoxy-4-hydroxy-
mandelic acid peak only in a small number of the sera
analyzed. In general, the serum concentration of 3-
methoxy-4-hydroxymandelic acid seems to be lower
than 20 MgA, and the same is true for CSF.
5-Hydroxyindolylacetic acid, the main metabolite of
serotonin, can be estimated by the same procedure. The
column temperature must be set higher, at 190 °C, to
get a retention time of about 6 minutes. It is detected
with about the sensitivity as homovanillic acid. Thus,
after the injection of the samples at 140 °C for the homo-
vanillic acid estimation, the same samples can be injected
once more at 190°C for 5-hydroxyindolylacetic acid.
H o m o v a n i l l i c a c i d i n s e r u m o f
n o r m a l s
We analyzed the sera of 42 normal volunteers, men and
women, aged between 22 and 60 years. A mean value of
62 ± 45 μg/l was found for the group, with a range from
7 to 186. The mean value corresponds to 340 ± 247
nmol/1 serum (1 μg/l corresponds to 5.49 nmol/1, and
for comparison with literature values, to 1 ng/ml). The
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Fig. 2. Distribution of homovanillic acid concentrations in cerebrospinal fluid and serum of the groups.
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vanillic acid concentrations in the group, with a peak
between 20 and 60 μg/l (54.7% of the population) and a
second one, smaller, with concentrations over 100 ^g/1
(28.4% of the population) (fig. 2). This kind of distribu-
tion is responsible for the great variation coefficient
found for the group (CV = 73%).
H o m o v a n i l l i c a c i d i n s e r u m a n d C S F
o f p s y c h o t i c p a t i e n t s
In a number of psychotic patients with paranoid-hallucinatory
syndrome, hospitalized in our clinic, lumbar punctures were
performed for routine analysis and estimation of catecholamine
metabolites in CSF. The cerebrospinal fluid was collected in
portions (0.5, 2, 2, 7, 2 ml), the patient being in a sitting
position, and stored immediately at -20 °C until analysis. After
the puncture 10 ml blood were taken and the serum separated
by centrifugation. We estimated homovanillic acid in the serum
and in the last CSF portion.
Table 1 shows the results of the homovanillic acid
estimations. Group II refers to a group of psychotic
patients with paranoid-hallucinatory syndrome who were
not under neuroleptic treatment when the CSF and
blood samples were taken. Group III is a group of
patients with the same symptomatology who were under
treatment with neuroleptics for a longer period, at least
one month. And group IV refers to 10 patients from the
group II, who were then treated in our clinic with
haloperidol; their CSF and blood were sampled again
after one month.
For the statistical evaluation of the results, we used the
Wilcoxon test for the small group IV, and the Student
tatest and linear regression test for the other groups. The
' results are shown in table 2.
The homovanillic acid concentrations in the sera from
the group of untreated patients did not differ from those
in the sera from the group of normals. In both, the
distribution was bimodal (fig. 2). Significantly higher
concentrations were found for the group of chronically
treated patients, compared to the group of normals.
Significantly elevated homovanillic acid concentrations
were also found in the CSF but not in serum after short
time treatment with neuroleptics. Thus, it can be
postulated that short-term treatment elevates the
homovanillic acid concentrations in C$F, while long-
term treatment elevates homovanillic acid in serum. This
could be an indication for some inhibition of homo-
vanillic acid transport from CSF to blood caused at the
beginning of the treatment with neuroleptics, parallel to
the known effect of increase in dopamine turnover.
The correlation between homovanillic acid concentrations
in serum and in CSF was tested by the linear regression
test and Spearman's correlation coefficient. No signifi-
cance was found for any group. We did not estimate
homovanillic acid in CSF of normals, so that the
question of whether there is a correlation normally can-
not be answered.
Tab. 1: Homovanillic acid concentrations (Mg/1) in serum of normals and in serum and CSF of psychotic patients.
Serum CSF
Group N mean ± S.D. range
Tab. 2. Statistical evaluation of the results mentioned in table 1.
mean ± S.D. range
I Normals
Π Patients, untreated
III Patients, chronically treated with
neuroleptics
IV Patients before treatment with haloperidol























































Group IV, serum, before treatment
Group IV, CSF, before treatment
Group II, serum
Group III, serum
Group IV, serum, before treatment
Group IV, serum, after treatment
compared to
group II, serum ' '
group III, serum
group IV, serum, after treatment
group IV, CSF, after treatment
group II, CSF
group Illi CSF
group IV, CSF, before treatment











t = + 1.2378 n.s.
t = + 1.7244 0.05
n.s.
0.05
r = - 0.2048 n.s.
r = + 0.1851 n.s.
r = + 0.4121 n.s.
r = 0.0000
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